A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A phase 2 trial of Alisertib in HR-positive / HER2-negative breast cancer, run by Puma Biotechnology, Inc., now recruiting.
Overview
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06369285 by Puma Biotechnology, Inc., with 225 participants planned, started 2024-11-19 and due to reach its primary completion in 2027-12-30. Interventions recorded: Alisertib and Endocrine therapy.
Similar pages
not linked directly; found by shared links- TrialA Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Shares Alisertib, Puma Biotechnology and the tag pipeline.
- TrialA Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Shares Alisertib, Puma Biotechnology.
- TrialStudy of TYK-00540 Tablets in Patients With Advanced Solid Tumors
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialComparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.